Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 13Active not recruiting 5Withdrawn 2Completed 2Terminated 1Not yet recruiting 1Approved for marketing 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Glioma 3Leukemia, Myeloid, Acute 2Cholangiocarcinoma 2Recurrence 1Neoplasms, Unknown Primary 1IDH1 Mutation Myeloid Neoplasms 1Chondrosarcoma 1

Interventions

Cytarabine 272Cyclophosphamide 136fludarabine phosphate 127Azacitidine 117Peripheral Blood Stem Cell Transplantation 95Busulfan 93Filgrastim 80Decitabine 79fludarabine 78Mycophenolic Acid 78Idarubicin 76Etoposide 76Whole-Body Irradiation 75Daunorubicin 72Tacrolimus 71Cyclosporine 64Methotrexate 62Mitoxantrone 57Clofarabine 55Antilymphocyte Serum 55Granulocyte Colony-Stimulating Factor 51Gemtuzumab 50Melphalan 49venetoclax 48Radiotherapy 30sargramostim 28Injections 25Bortezomib 25thymoglobulin 24aldesleukin 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Leukemia, Myeloid, Acute × ivosidenib × Clear all
NCT06181734 2026-02-10

CONFIDHENCE

iOMEDICO AG

Completed
8 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04176393 2023-02-13

A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation

CStone Pharmaceuticals

Phase 1 Completed
30 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡